Loading data for VCYT — first visit, this takes a few seconds.
Veracyte, Inc. (VCYT)
NasdaqGM: VCYT
· 即時價格 · USD
43.34
-1.91 (-4.22%)
收盤價： Aug 28, 2026, 8:00 PM
43.47
+0.30%
盤前: 7:00 AM
股價、關鍵數字和最新消息，都在這一頁。
Veracyte, Inc.（VCYT）股價、分析與資料
無可用資料
| 買價 | 33.3 |
| 市值 | 3.48B |
| 營收 (ttm) | 562M |
| 淨利（ttm） | 114M |
| 1.94 | |
| 1.4 | |
| 30.96 | |
| 22.25 | |
| P/B (ttm) | 2.51 |
| P/S (ttm) | 6.20 |
| 財報日期 | Nov 3, 2026 |
| 賣價 | 59.52 |
| 成交量 | 1,684,116 |
| 20 日平均成交量 | 1,366,779 |
| 開盤價 | 45.20 |
| 前收盤價 | 45.25 |
| 當日區間 | 43.32 - 45.55 |
| 52 週範圍 | 29.38 - 60.91 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 VCYT
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nC...
完整的公司簡介財報驚奇
Veracyte 已於 Jul 30, 2026 公布季度財報：
- 營收為 $150.32M 低於預期 $0, 年增 15.49% 成長.
- 每股盈餘為 0.54 超出預期 0.11, 年增 22.73% 成長.
第 1 頁，共 2 頁